65,437 trials
Peripheral T Cell Lymphoma · Transformed Mycosis Fungoides
Primary: Overall Response Rate Assessed by Independent Review Committee Based on PET-CT — 32.4 percentage — p=0.051
Pompe Disease
Primary: Off-ventilator Spontaneous Breathing (SB) at Baseline and Day 180 — 0.52; 4.72 hours per day
Human Cancers
Primary: Serious Adverse Events (SAEs) and Non-serious Adverse Events (AEs) Considered to be at Least Possibly Related to MOv18 IgE — 0; 5; 2; 0 Participants
Mild Cognitive Impairment · Cognitive Decline · Gait Disorders in Old Age
Primary: Change in 4-Meter Gait Speed (Section 2 of the Short Physical Performance Battery) — 0.79; 0.82; 0.79 Meters/Second
Major Depressive Disorder
Primary: Percentage Change in Prefrontal Cortex (PFC) Cerebral Blood Flow (CBF) During High-Irradiance t-PBM — 1.12 Percent change in raw frontal BOLD
Delayed Graft Function
Primary: Number of Days Needed to Recover From Delayed Graft Function (DGF) — 14.0; 15.0 days
Fatigue · Quality of Life
Primary: Fatigue Severity Scale (FSS) — 4; 2 Participants
Mental Health
Primary: Coping Self-efficacy — 3.32; 3.64; 3.92; 3.85 score on a scale
Cancer · Pain Management · Opioid Use
Primary: Frequency of Patient Log Ins — 14 log ins to the application per patient
Occipital Neuralgia
Primary: A Reduction in Either Pain Frequency or Severity Associated With Occipital Neuralgia. — 2.5; 2.7 point improvement
Hot Flushes · Hot Flashes
Primary: Change in Number of Night Sweats From Baseline to 6 Months After Intervention. — 5.46; 10.09 night sweats/month
Chronic Pain
Primary: Pain Response — 58; 54 Participants
Type 1 Diabetes
Primary: Percentage of Time in Target Range of 70-180 mg/dL. — 49.64; 48.86; 60.78; 50.1 percent time spent 70 mg/dL - 180 mg/dL
End Stage Renal Failure on Dialysis
Primary: Patients' Adherence to Study Protocol — 22; 24; 19; 19 Participants
COVID-19
Primary: Proportion of Participants Alive and Without Mechanical Ventilation Through Day 29 in Participants With Baseline Ordinal Score of 5 or 6, C-reactive Protein…